Cancer Drug Discovery & Development Accelerator

A platform for integrated drug discovery and translation

When Lawrence Einhorn, MD, developed the cure for testicular cancer in the early 1970s, he gave hope to thousands of patients around the world and inspired countless cancer researchers to develop other therapies that might one day cure other cancers.

In 2019, IU Simon Comprehensive Cancer Center launched the Cancer Drug Discovery and Development Accelerator (CD³A) initiative, with the goal of integrating emerging technologies/equipment and computational tools for new drug discovery and development.

The CD³A division of the IU Melvin and Bren Simon Comprehensive Cancer Center operates as a non-profit organization that accelerates drug discovery and development by bringing together university researchers, experienced pharmaceutical industry veterans, technology cores, and external research organizations.

Led by program co-leaders Chafiq Hamdouchi, PhD, and Mark Kelley, PhD, our primary focus is expanding accessible molecular space and drug development capabilities across and within our research cores.